Back to search

Article

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

2020-04-29

Abstract excerpt

<title>Abstract</title> <p><bold>Objectives: </bold>B-cell depletion by rituximab (RTX) is an effective treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). However, peripheral B cell phenotypes and the selection criteria for RTX therapy in AAV remain unclear.<bold>Methods:</bold> Phenotypic characterization of circulating B cells was performed by 8-color flow cytometric anal...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
435985a1-14c6-5085-aa96-1ad9c08102d3
DOI
10.21203/rs.2.23827/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiationDOI 10.21203/rs.2.23827/v2
Select a neighboring publication to make it the new centre.